The emerging role of Klotho in clinical nephrology

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Klotho is highly expressed in the kidney and a soluble form of Klotho functions as an endocrine substance that exerts multiple actions including the modulation of renal solute transport and the protection of the kidney from a variety of insults in experimental models. At present, the Klotho database is still largely preclinical, but the anticipated forthcoming impact on clinical nephrology can be immense. This manuscript puts these potentials into perspective for the clinician. There is renal and systemic Klotho deficiency in both acute kidney injury (AKI) and chronic kidney disease (CKD). Klotho plummets very early and severely in AKI and represents a pathogenic factor that exacerbates acute kidney damage. In CKD, Klotho deficiency exerts a significant impact on progression of renal disease and extra renal complications. In AKI, soluble Klotho levels in plasma and/or urine may serve as an early biomarker for kidney parenchymal injury. Restoration by exogenous supplementation or stimulation of endogenous Klotho may prevent and/or ameliorate kidney injury and mitigate CKD development. In CKD, Klotho levels may be an indicator of early disease and predict the rate of progression, and presence and severity of soft tissue calcification. The correction of Klotho deficiency may delay progression and forestall development of extra renal complications in CKD. Rarely does one find a molecule with such broad potential applications in nephrology. Klotho can possibly emerge on the horizon as a candidate for an unprecedented sole biomarker and intervention. Nephrologists should monitor the progress of the preclinical studies and the imminently emerging human database.

Original languageEnglish (US)
Pages (from-to)2650-2657
Number of pages8
JournalNephrology Dialysis Transplantation
Volume27
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Nephrology
Kidney
Chronic Renal Insufficiency
Acute Kidney Injury
Biomarkers
Databases
Wounds and Injuries
Disease Progression
Theoretical Models
Urine

Keywords

  • acute kidney injury
  • biomarker
  • cardiac hypertrophy
  • chronic kidney disease
  • FGF23
  • Klotho
  • prognosis
  • secondary hyperparathyroidism

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

The emerging role of Klotho in clinical nephrology. / Hu, Ming C; Kuro-o, Makoto; Moe, Orson W.

In: Nephrology Dialysis Transplantation, Vol. 27, No. 7, 07.2012, p. 2650-2657.

Research output: Contribution to journalArticle

@article{61f906fafdbf4fc98289a4a53bb19853,
title = "The emerging role of Klotho in clinical nephrology",
abstract = "Klotho is highly expressed in the kidney and a soluble form of Klotho functions as an endocrine substance that exerts multiple actions including the modulation of renal solute transport and the protection of the kidney from a variety of insults in experimental models. At present, the Klotho database is still largely preclinical, but the anticipated forthcoming impact on clinical nephrology can be immense. This manuscript puts these potentials into perspective for the clinician. There is renal and systemic Klotho deficiency in both acute kidney injury (AKI) and chronic kidney disease (CKD). Klotho plummets very early and severely in AKI and represents a pathogenic factor that exacerbates acute kidney damage. In CKD, Klotho deficiency exerts a significant impact on progression of renal disease and extra renal complications. In AKI, soluble Klotho levels in plasma and/or urine may serve as an early biomarker for kidney parenchymal injury. Restoration by exogenous supplementation or stimulation of endogenous Klotho may prevent and/or ameliorate kidney injury and mitigate CKD development. In CKD, Klotho levels may be an indicator of early disease and predict the rate of progression, and presence and severity of soft tissue calcification. The correction of Klotho deficiency may delay progression and forestall development of extra renal complications in CKD. Rarely does one find a molecule with such broad potential applications in nephrology. Klotho can possibly emerge on the horizon as a candidate for an unprecedented sole biomarker and intervention. Nephrologists should monitor the progress of the preclinical studies and the imminently emerging human database.",
keywords = "acute kidney injury, biomarker, cardiac hypertrophy, chronic kidney disease, FGF23, Klotho, prognosis, secondary hyperparathyroidism",
author = "Hu, {Ming C} and Makoto Kuro-o and Moe, {Orson W}",
year = "2012",
month = "7",
doi = "10.1093/ndt/gfs160",
language = "English (US)",
volume = "27",
pages = "2650--2657",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - The emerging role of Klotho in clinical nephrology

AU - Hu, Ming C

AU - Kuro-o, Makoto

AU - Moe, Orson W

PY - 2012/7

Y1 - 2012/7

N2 - Klotho is highly expressed in the kidney and a soluble form of Klotho functions as an endocrine substance that exerts multiple actions including the modulation of renal solute transport and the protection of the kidney from a variety of insults in experimental models. At present, the Klotho database is still largely preclinical, but the anticipated forthcoming impact on clinical nephrology can be immense. This manuscript puts these potentials into perspective for the clinician. There is renal and systemic Klotho deficiency in both acute kidney injury (AKI) and chronic kidney disease (CKD). Klotho plummets very early and severely in AKI and represents a pathogenic factor that exacerbates acute kidney damage. In CKD, Klotho deficiency exerts a significant impact on progression of renal disease and extra renal complications. In AKI, soluble Klotho levels in plasma and/or urine may serve as an early biomarker for kidney parenchymal injury. Restoration by exogenous supplementation or stimulation of endogenous Klotho may prevent and/or ameliorate kidney injury and mitigate CKD development. In CKD, Klotho levels may be an indicator of early disease and predict the rate of progression, and presence and severity of soft tissue calcification. The correction of Klotho deficiency may delay progression and forestall development of extra renal complications in CKD. Rarely does one find a molecule with such broad potential applications in nephrology. Klotho can possibly emerge on the horizon as a candidate for an unprecedented sole biomarker and intervention. Nephrologists should monitor the progress of the preclinical studies and the imminently emerging human database.

AB - Klotho is highly expressed in the kidney and a soluble form of Klotho functions as an endocrine substance that exerts multiple actions including the modulation of renal solute transport and the protection of the kidney from a variety of insults in experimental models. At present, the Klotho database is still largely preclinical, but the anticipated forthcoming impact on clinical nephrology can be immense. This manuscript puts these potentials into perspective for the clinician. There is renal and systemic Klotho deficiency in both acute kidney injury (AKI) and chronic kidney disease (CKD). Klotho plummets very early and severely in AKI and represents a pathogenic factor that exacerbates acute kidney damage. In CKD, Klotho deficiency exerts a significant impact on progression of renal disease and extra renal complications. In AKI, soluble Klotho levels in plasma and/or urine may serve as an early biomarker for kidney parenchymal injury. Restoration by exogenous supplementation or stimulation of endogenous Klotho may prevent and/or ameliorate kidney injury and mitigate CKD development. In CKD, Klotho levels may be an indicator of early disease and predict the rate of progression, and presence and severity of soft tissue calcification. The correction of Klotho deficiency may delay progression and forestall development of extra renal complications in CKD. Rarely does one find a molecule with such broad potential applications in nephrology. Klotho can possibly emerge on the horizon as a candidate for an unprecedented sole biomarker and intervention. Nephrologists should monitor the progress of the preclinical studies and the imminently emerging human database.

KW - acute kidney injury

KW - biomarker

KW - cardiac hypertrophy

KW - chronic kidney disease

KW - FGF23

KW - Klotho

KW - prognosis

KW - secondary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=84864398735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864398735&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfs160

DO - 10.1093/ndt/gfs160

M3 - Article

VL - 27

SP - 2650

EP - 2657

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 7

ER -